San Diego-centered Viking Therapeutics marked itself as a significant competitor while in the weight loss drug marketplace in February just after revealing promising details from the mid-stage trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when specified as a weekly injection and in March the